This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CNCR Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisHoldingsRatingsShort InterestTrendsBuy This Stock About Range Cancer Therapeutics ETF (NASDAQ:CNCR) 30 days 90 days 365 days Advanced Chart Get CNCR alerts:Sign Up Key Stats Today's Range$11.63▼$11.8250-Day Range$27.45▼$32.2552-Week Range$7.88▼$16.27Volume1,757 shsAverage Volume4,171 shsMarket Capitalization$7.28 millionAssets Under Management$6.95 millionDividend Yield3.11%Net Expense Ratio0.79%Aggregate RatingModerate Buy ETF OverviewThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.Read More… Range Cancer Therapeutics ETF ExpensesTypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.79%0.57%0.57%0.54%0.53%Other Expenses0.00%0.30%0.48%0.42%0.51%Total Expense0.79%0.70%0.72%0.68%0.71%Fee Waiver0.00%-0.45%-0.49%-0.29%-0.54%Net Expense0.79%0.61%0.63%0.62%0.60% Receive CNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address CNCR ETF News HeadlinesTango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge FundsNovember 23, 2024 | msn.comBuy Rating Affirmed for TScan Therapeutics Amid Positive Developments in TCR-T Cell Therapy SpaceOctober 12, 2024 | markets.businessinsider.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.June 6, 2025 | American Alternative (Ad)Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC SubpopulationSeptember 9, 2024 | seekingalpha.comRange Oncology Therapeutics Index ETF (CNCR)August 15, 2024 | finance.yahoo.comTango Therapeutics Shuts Early-Stage Cancer Study Due To Liver ToxicityMay 23, 2024 | msn.comSee More Headlines CNCR ETF - Frequently Asked Questions What other stocks do shareholders of Range Cancer Therapeutics ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Range Cancer Therapeutics ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Fund Details IssuerExchange Traded Concepts Fund NameRange Cancer Therapeutics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CNCR Inception Date10/13/2015 Fund ManagerDenise M. Krisko WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkRange Oncology Therapeutics Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings1 Fund Statistics Assets Under Management$6.95 million Average Daily Volume$2,265.70 Discount/Premium0.12% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorExchange Traded Concepts, LLC CustodianU.S. Bank, N.A. DistributorQuasar Distributors, LLC Transfer AgentU.S. Bank, N.A. TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest6,900 shs Miscellaneous Outstanding Shares780,814Beta0.95 Creation Unit50,000 Creation Fee$150.00 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report Top 10 CNCR HoldingsFirst American Government Obligations FundHolding Weight: 3.01%Summit Therapeutics (NASDAQ:SMMT)Holding Weight: 2.24%Blueprint Medicines (NASDAQ:BPMC)Holding Weight: 1.98%iTeos Therapeutics (NASDAQ:ITOS)Holding Weight: 1.95%Nuvation Bio (NYSE:NUVB)Holding Weight: 1.92%Ginkgo Bioworks (NYSE:DNA)Holding Weight: 1.91%Fate Therapeutics (NASDAQ:FATE)Holding Weight: 1.90%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 1.87%Innate Pharma (NASDAQ:IPHA)Holding Weight: 1.84%Exelixis (NASDAQ:EXEL)Holding Weight: 1.83%Full Holdings Details This page (NASDAQ:CNCR) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Wealth Reset: Could You Be The First Beneficiary?Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major shift is coming this July — and Wall Street isn't waiting around. Thanks to a new rule going into e...American Alternative | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | SponsoredThe Age of Chaos has begunThis is one of the most confusing markets in history. We have entered an Age of Chaos. And you must take...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.